Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: A study in healthy male subjects

Canadian Journal of Physiology and Pharmacology

Volumn 74, Issue 8, 1996, Pages 887-893

  Nony, P ^a,c   Ffrench, P ^a   Girard, P ^a   Delair, S ^a   Azoulay, S ^b   Girre, J P ^b   Dechavanne, M ^a   Boissel, J P ^a  

^a Cardiovascular Hospital   (France)

^b Laboratoires Houdé   (France)

^c LOUIS PRADEL HOSPITAL   (France)

Author keywords

Beraprost; Hemodynamics; Platelet aggregation; Prostacyclin analogue

Indexed keywords

BERAPROST; PLACEBO; PROSTACYCLIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0030447568     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y96-088     Document Type: Article

References (28)

1. 2 analogue. Br. J. Pharmacol. 89: 703-711.
2. Born, G.V.R. 1962a. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (London), 194: 927-929.
3. Born, G.V.R. 1962b. Quantitative investigations into the aggregation of blood platelets. J. Physiol. (London), 162: 67-71.
4. Darling, R.C., Raines, J.K., Brener, B.J., and Austen, W.G. 1972. Quantitative segmental pulse volume recorder: a clinical tool. Surgery (St. Louis), 72: 873-887.
5. Demolis, J.-L., Robert, A., Mouren, M., Funck-Brentano, C., and Jaillon, P. 1993. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J. Cardiovasc. Pharmacol. 22: 711-716.
6. Fuller, H.D. 1994. Evaluation of left ventricular function by impedance cardiography: a review. Prog. Cardiovasc. Dis. 36: 267-273.
7. Greaves, M. 1990. Platelet function tests in the assessment of antithrombic agents. Br. J. Pharmacol. 30: 175-176.
8. Ikeda, Y., and Uji, Y. 1992. Effect of beraprost sodium (TRK-100) on platelet aggregation. A single administration test. Modern Med. Care, 24: 135-140.
9. Isaka, Y., Handa, N., Imaizumi, M., Kimura, K., and Kamada, T. 1991. Effect of TRK-100, a stable orally active prostacyclin analogue, on platelet function and plaque size in atherothrombic strokes. Thromb. Haemostasis, 65: 344-350.
10. Kajikawa, N., Nogimori, K., Murata, T., Nishio, S., and Uchiyama, S. 1989. Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneim. Forsch. 39: 495-499.
11. Kato, R., Uji, Y., and Matsumoto, K. 1989a. Phase I study of beraprost sodium (TRK-100), a prostacyclin derivative. Single oral administration study. Jpn. J. Clin. Pharmacol. Ther. 20: 515-516.
12. Kato, R., Uji, Y., and Matsumoto, K. 1989b. Phase I study of beraprost sodium (TRK-100), a prostacyclin derivative. Repeated oral administration study for 10 days. Jpn. J. Clin. Pharmacol. Ther. 20: 529.
13. Krause, W., and Krais, T. 1986. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur. J. Clin. Pharmacol. 30: 61-68.
14. Kubicek, W.G., Kottke, F.J., Rumos, M.U., Patterson, R.P., Witsoe, D.A., Labree, J.W., Remole, W., Layman, T.E., Schoening, H., and Garamella, J.T. 1974. The Minnesota impedance cardiographtheory and applications. Biomed. Eng. 9: 410-416.
15. Kurihara, J., Sahara, T., and Kato, H. 1990. Protective effect of beraprost sodium, a new chemically stable prostacyclin analogue, against the deterioration of baroreceptor reflex following transient global cerebral ischaemia in dogs. Br. J. Pharmacol. 99: 91-96.
16. Moncada, S. 1983. Biology and therapeutic potential of prostacyclin. Stroke, 14: 157-168.
17. 2, prostacyclin and other cicosanoids in the cardiovascular system. Therapie, 46: 217-221.
18. Murata, T., Sakaya, S., Hoshino, T., Umetsu, T., Hirano, T., and Nishio, S. 1989a. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system. Arzneim. Forsch. 39(II): 860-866.
19. Murata, T., Murai, T., Kanai, T., Ogaki, Y., Sanai, K., Kanda, H., Sato, S., Kajikawa, N., Umetsu, T., and Matsuura, H., et al. 1989b. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomie, cardiovascular and gastrointestinal systems, and other effects. Arzneim. Forsch. 39(II): 867-876.
20. Nishio, SK., Matsuura, H., Kanai, N., Fukatsu, Y., Hirano, T., Nishikawa, N., Kameoka, K., and Umetsu, T. 1988. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analogue, in several species. Jpn. J. Pharmacol. 47: 1-10.
21. Nishio, S.K., Matsuura, H., Hattori, M., Endoh, T., Yamada, N., and Hirano, T. 1989. Cardiovascular effects of beraprost sodium (TRK-100), a prostacyclin analogue in the dog. Folia Pharmacol. Jpn. 94: 351-361.
22. Rossi, E.C., and Louis, G. 1977. Kinetic parameters of platelet aggregation as an expression of platelet responsiveness. Thromb. Haemostasis, 37: 283-290.
23. Saito, T., Saitoh, S., Asakura, T., Kanke, M., Owada, K., and Maruyama, Y. 1993. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model. Int. J. Cardiol. 38: 225-233.
24. Sakaguchi, S., Tanabe, T., and Mishima, Y. 1989. Clinical evaluation of the efficacy of beraprost sodium, a prostacyclin derivative, on chronic arterial occlusion. Med. Consul New Rem. 26: 32.
25. Sim, A.K., McCraw, A.P., Cleland, M.E., and Umetsu, T. 1985. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneim. Forsch. Drug Res. 35: 1816-1818.
26. Takeo, S. 1992. Pharmacodynamics and clinical studies with beraprost sodium, a drug for peripheral vascular disease. Cardiovasc. Drug Rev. 10: 392-403.
27. Toda, N. 1988. Beraprost sodium. Cardiovasc. Drug Rev. 6: 222-238.
28. Umetsu, T., Murata, T., and Nishio, S. 1989. Studies on the anti-platelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneim. Forsch. Drug Res. 39: 68-73.